NASDAQ: SLBTSl Science Holding Ltd Stock
$2.79+0.06 (+2.2%)
Updated Sep 1, 2026
SLBT Price
$2.79
Fair Value Price
N/A
Market Cap
$1.56B
52 Week Low
$2.51
52 Week High
$14.50
P/E
N/A
P/B
685.02x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$2.20M
Earnings
$1.31M
Gross Margin
N/A
Operating Margin
-173.85%
Profit Margin
-173.8%
Debt to Equity
0.23
Operating Cash Flow
-$972k
Beta
0.04
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
SLBT Overview
SL Science Holding Limited manufactures cosmetic skin care and scalp care products. The company’s products include SL bio’s milk-derived exosome essence, SL bio’s tangerine-derived extract, and the MilkExo concentrate series. It also offers research services in armed T-cells, gamma delta T- cells, citrus reticulata (tangerine) extract, and milk-derived exosomes. SL Science Holding Limited was formerly known as SL BIO Co., Ltd. and changed its name to SL Science Holding Limited in June 2026. The company is based in Taipei, Taiwan.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SLBT's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
SLBT
Ranked#182 of 463
Ranked#182 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.35 | A | |
| $113.38 | A | |
| $6.86 | A |
Be the first to know about important SLBT news, forecast changes, insider trades & much more!
SLBT News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SLBT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SLBT is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
SLBT is poor value based on its book value relative to its share price (685.02x), compared to the US Biotechnology industry average (5.5x)
P/B vs Industry Valuation
SLBT is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more SLBT due diligence checks available for Premium users.
Valuation
SLBT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0x
Industry
15.43x
Market
40.12x
SLBT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
685.02x
Industry
5.5x
SLBT is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SLBT's financial health
Profit margin
Revenue
$0.0
Net Income
-$29.1k
Profit Margin
0%
SLBT's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
SLBT's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$39.5M
Liabilities
$39.3M
Debt to equity
-22.05
SLBT's short-term assets ($1.43M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SLBT's short-term assets ($1.43M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SLBT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$215.0k
Investing
$34.1M
Financing
-$33.9M
SLBT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SLBT vs Biotech Stocks
Sl Science Holding Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.